Leah Nakamura, MD
Urogynecology and Reconstructive Pelvic Surgery · Laguna Hills, CANPI 1063626893
Payments from drug & device makers
Across 534 payments — averaging $31.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Axonics, Inc.$3K
- Caldera Medical, Inc$2K
- AbbVie$1K
- Sumitomo Pharma America, Inc.$1000
- Coloplast$857
- plus $5K from 32 others
What the payments were for
- Travel & lodging$1,1477%
- Food & beverage$15,16690%
- Education$2251%
- Gifts$2261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 85 | $4,078 |
| Axonics, Inc. | 115 | $2,926 |
| Caldera Medical, Inc | 20 | $1,586 |
| AbbVie(2 entities) | 57 | $1,013 |
| Sumitomo Pharma America, Inc. | 71 | $1,000 |
| Coloplast | 14 | $857 |
| Boston Scientific | 13 | $675 |
| Bluewind Medical | 19 | $666 |
| Astellas Pharma US Inc | 29 | $598 |
| Valencia Technologies Corporation | 3 | $550 |
| Contura, Inc. | 3 | $367 |
| Pfizer | 23 | $343 |
| Urovant Sciences Inc | 31 | $307 |
| Femselect Inc. | 4 | $228 |
| Antares Pharma, Inc. | 10 | $196 |
| Calyxo, Inc. | 3 | $166 |
| Histosonics, Inc. | 1 | $148 |
| Urogen Pharma, Inc. | 4 | $131 |
| Teleflex LLC | 4 | $123 |
| Dornier Medtech America, Inc | 1 | $104 |
| Urocure LLC | 1 | $99 |
| Palette Life Sciences, Inc. | 3 | $66 |
| Ferring Pharmaceuticals Inc. | 2 | $61 |
| Tolmar, Inc. | 2 | $53 |
| Merck | 2 | $53 |
| Davol Inc. | 1 | $51 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $42 |
| Johnson & Johnson | 2 | $41 |
| Bioprotect Medical, Inc. | 1 | $31 |
| BD | 1 | $28 |
| Halozyme Inc | 1 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Accord Healthcare, Inc. | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $23 |
| Novartis | 1 | $23 |
| Myovant Sciences Inc. | 1 | $22 |
| Coopersurgical, Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,770
- Desara$1,031
- ALTIS$625
- ALTAVIVA$477
- eCoin Device Kit$459
- Bulkamid$292
- Axonics$258
- AMS 700$150
- Solyx SIS System$148
- REVI$138
- CVAC Aspiration System$129
- Advantage System$125
- GEMTESA$107
- Consumables & Accessories$104
How this compares
$16,764 in reported general payments places this provider in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 756 | $658,363 |
| MyrbetriqMirabegron | 233 | $185,816 |
| PremarinEstrogens, Conjugated | 127 | $55,384 |
| Estradiol | 592 | $41,711 |
| Methenamine Hippurate | 376 | $35,159 |
| Trospium Chloride ErTrospium Chloride | 62 | $20,373 |
| NitrofurantoinNitrofurantoin Macrocrystal | 213 | $9,556 |
| Mirabegron ErMirabegron | 12 | $7,702 |
| ToviazFesoterodine Fumarate | 15 | $6,757 |
| Trospium Chloride | 110 | $6,678 |
| EstringEstradiol | 11 | $5,553 |
| YuvafemEstradiol | 23 | $3,933 |
| Tolterodine Tartrate ErTolterodine Tartrate | 31 | $3,700 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 337 | $3,518 |
| Cephalexin | 154 | $2,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,000 | $658,363756 claims |
| Astellas Pharma US IncMyrbetriq | $598 | $185,816233 claims |
| PfizerPremarin, Toviaz, Estring | $343 | $67,694153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Laguna Hills
- Poone ShoureshiLaguna Hills$20K
- Bilal KaakiRiverside$431K
- Andrew BrillSan Francisco$345K
- Tanaz FerzandiLos Angeles$344K
- Savitha KrishnanMountain View$243K
- Felicia LaneOrange$121K
- Bruce Kahnla Jolla$114K
- Christopher TarnayLos Angeles$102K
- Peter CastilloLos Gatos$95K
- Azin ShahryarinejadManhattan Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.